Get started
Live feed
·
PRReleasevia Quantisnow
Altimmune Inc. logo

Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021

ByQuantisnow·Wall Street's wire, on your screen.
ALTAltimmune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALT (Altimmune Inc.) and more on Quantisnow.